The pipeline
17 programmes in development for hair loss and hair regeneration. Sorted by phase, latest first.
17 programmes
| Programme | Developer | Phase | Approach | Mechanism | Last activity |
|---|---|---|---|---|---|
| Minoxidil (topical) High· 38 trials | Unknown | Approved | Topical | Potassium channel opener | 1 month ago |
| Topical finasteride High· 3 trials | Almirall | Approved | Topical | 5α-reductase inhibitor | No public activity in over 18 months |
| Coacillium (LH-8) High | Legacy Healthcare | Filed with regulator | Topical | Other | Never |
| Clascoterone (Breezula) High· 2 trials | Cosmo Pharmaceuticals | Phase 3 | Topical | Androgen receptor | 2 months ago |
| DA-001 / DA-002 / DA-005 Medium· 6 trials | Applied Biology | Phase 3 | Topical | Adrenergic | 4 months ago |
| Jaktinib High· 4 trials | Suzhou Zelgen Biopharmaceuticals | Phase 3 | OralTopical | JAK inhibitor | 17 months ago |
| Pyrilutamide High· 7 trials | Kintor Pharmaceutical | Phase 3 | Topical | Androgen receptor | No public activity in over 18 months |
| TH07 Low· 1 trials | Triple Hair | Phase 3 | Topical | Undisclosed | 5 months ago |
| Dalosirvat (SM-04554) Medium· 3 trials | Biosplice Therapeutics | Phase 2/3 | Topical | Wnt pathway | No public activity in over 18 months |
| CG 428 Low· 3 trials | Legacy Healthcare | Phase 2 | Topical | Undisclosed | No public activity in over 18 months |
| Delgocitinib (LEO 124249) High· 5 trials | LEO Pharma | Phase 2 | Topical | JAK inhibitor | 1 month ago |
| GT20029 Medium· 3 trials | Kintor Pharmaceutical | Phase 2 | Topical | Androgen receptor | No public activity in over 18 months |
| PP405 High· 1 trials | Pelage Pharmaceuticals | Phase 2 | Topical | Metabolic / mitochondrial | 8 months ago |
| TDM-105795 Medium· 4 trials | TechnoDerma Medicines | Phase 2 | Topical | Thyroid hormone receptor | 9 months ago |
| DLQ-01 (latanoprost) Medium· 1 trials | DermaLiq Therapeutics | Phase 1/2 | Topical | Prostaglandin | No public activity in over 18 months |
| ET-02 Medium | Eirion Therapeutics | Phase 1 | Topical | Stem cell activation | Never |
| ANR-001.1 (latanoprost + minoxidil) Low | Aneira Pharma | Phase 0 | Topical | Combination | Never |